Cholesterol and Health in Old Age: Risk Factor or Risk Marker?

Journal of the American Geriatrics Society

Volumn 52, Issue 4, 2004, Pages 639-640

  Harris, Tamara B ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; LIPID; MARKER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL CONSUMPTION; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL METABOLISM; CHRONIC DISEASE; COGNITION; DISEASE ASSOCIATION; DRINKING; EDITORIAL; EPIDEMIOLOGICAL DATA; HEALTH STATUS; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFECTION; LIVER FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; PHYSICAL ACTIVITY; RISK FACTOR; SENESCENCE; SMOKING; STRESS; VASCULAR DISEASE;

AGE FACTORS; AGED; AGING; BIOLOGICAL MARKERS; CHOLESTEROL; EPIDEMIOLOGIC METHODS; EPIDEMIOLOGIC STUDIES; HEALTH STATUS; HUMANS; HYPERCHOLESTEROLEMIA; RISK ASSESSMENT; RISK FACTORS;

EID: 1842733425     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2004.52176.x     Document Type: Editorial

References (18)

1. Karlamangla AS, Singer BH, Reuben DB et al. Increases in serum non-high-density lipoprotein cholesterol may be beneficial in some high-functioning older adults: MacArthur Studies of Successful Aging. J Am Geriatr Soc 2004;52:487-494.
2. Cronin-Stubbs D, Beckett LA, Scherr PA et al. Weight loss in people with Alzheimer's disease: A prospective population based analysis. BMJ 1997; 314:178-179.
3. Schultz Jr. NZ, Dineen JT, Elias MF et al. WAIS performance for different age groups of hypertensive and control subjects during the administration of a diuretic. J Gerontol 1979;34:246-253.
4. Launer LJ, Masaki K, Petrovitch H et al. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995;274:1846-1851.
5. Jacobs Jr. DR, Hebert B, Hebert, Schreiner PJ et al. Reduced cholesterol is associated with recent minor illness. The CARDIA Study. Coronary Artery Risk Development in Young Adults. Am J Epidemiol 1997;146:558-564.
6. Sniderman AD, Teng B. Predictable changes in low density lipoprotein composition after acute myocardial infarction. Atherosclerosis 1977;27:361-368.
7. Schatzkin A, Hoover RN, Taylor PR et al. Serum cholesterol and cancer in the NHANES I epidemiologic followup study. National Health and Nutrition Examination Survey. Lancet 1987;2:298-301.
8. Kritchevsky SB, Wilcosky TC, Morris DL et al. Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. Cancer Res 1991;51:3198-3203.
9. Ueyama Y, Matsuzawa Y, Yamashita S et al. Hypocholesterolaemic factor from gallbladder cancer cells. Lancet 1990;336:707-709.
10. Nimer SD, Champlin RE, Golde DW. Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor. JAMA 1988;260:3297-3300.
11. Jacobs D, Blackburn H, Higgins M et al. Report of the Conference on Low Blood Cholesterol: Mortality associations. Circulation 1992;86:1046-1060.
12. Kagan A, McGee DL, Yano K et al. Serum cholesterol and mortality in a Japanese-American population. The Honolulu Heart Program. Am J Epidemiol 1981;114:11-20.
13. Schatz IJ, Masaki K, Yano K et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: A cohort study. Lancet 2001;358:351-355.
14. Iribarren C, Reed DM, Burchfiel CM et al. Serum total cholesterol and mortality. Confounding factors and risk modification in Japanese-American men. JAMA 1995;273:1926-1932.
15. Harris T, Feldman JJ, Kleinman JC et al. The low cholesterol-mortality association in a national cohort. J Clin Epidemiol 1992;45:595-601.
16. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987;257:2176-2180.
17. Barzilai N, Atzmon G, Schechter C et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003;290:2030-2040.
18. Shepherd J, Blauw GJ, Murphy MB. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-1630.